Local, language-minority and Latin American news sites join the Trust Project
The public will now hear, see and read about their journalists, where they got their information and what policies guide them. Among other disclosures, they will see opinion clearly separated from news, find corrections for any errors easily, and as the Trust Project deepens its attention to ethical use of artificial intelligence, gain a concrete understanding of each site's use of AI tools in newsgathering and production.
The Trust Project ® welcomes The Beacon, a growing force in Kansas and Missouri that fills critical news gaps and provides free news stories to other publishers; BioBioChile, which explores issues throughout Chile with the country's cultural, social and economic diversity in mind; El Diario, which explains the news in Venezuela with depth to support public discourse; and Le Courrier de la Nouvelle-Écosse, which serves the French-speaking minority in Nova Scotia. El Diario and BioBioChile are the first news organizations in their countries to participate. All made substantial upgrades to their standards and overall transparency. The public can easily see why their news is worth attention and trust – and hold them accountable.
"We work closely with news organizations globally to strengthen the clear value of their journalism to the public," said Trust Project founder and CEO Sally Lehrman. "We're proud of the many changes these incoming news partners made to earn well-deserved confidence through transparency and integrity, including in their use of AI."
More than 300 fully approved Trust Project news partners continue to build integrity into every aspect of their journalism: newsgathering; news presentation online, in audio and video; even in their business operations. When news outlets complete the Trust Indicators in policy and practice, they earn the Trust Mark.
The Trust Indicators® empower people to stay informed and thrive by making it easy to choose news with confidence.
The Trust Project is grateful to our funders, who support our research on trust, workshops and training, and ongoing work with Trust Project Network sites and others to build a trustworthy news ecosystem the public values. Learn about making a donation here.
About the Trust Project:
8 Trust Indicators®, a collaborative, journalism-generated and proven standard that helps both regular people and algorithms easily assess the authority and integrity of news. Polices and standards are shaped through user research and enforced independently from the project's funding sources. For more, visit: https://thetrustproject.org/faq/.
Media Contact:
Jessica Sterling, 650-728-8211
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Health Canada Approves Dual Immunotherapy OPDIVO® Plus YERVOY® for Colorectal and Liver Cancers Français
MONTREAL, Aug. 19, 2025 /CNW/ - Bristol Myers Squibb Canada (BMS) today announced that Health Canada has approved OPDIVO ® (nivolumab) in combination with YERVOY ® (ipilimumab) for the first-line treatment of adult patients with: unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), and unresectable or advanced hepatocellular carcinoma (HCC) 1. This dual immunotherapy regimen offers a new first-line treatment approach for two challenging gastrointestinal cancers, supported by two pivotal Phase 3 trials: CheckMate-8HW in CRC which demonstrated improvement in progression-free survival, and CheckMate-9DW in HCC which showed improvements in survival—each compared to existing standard therapies 1. "Although we've seen progress, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer is clinically complex, particularly in the first-line setting where there remains an ongoing need for additional treatments," said Vancouver-based medical oncologist, Dr. Sharlene Gill. "The approval of OPDIVO ® plus YERVOY ®, supported by CheckMate-8HW, the largest phase 3 immunotherapy trial to date in this population, offers a well-studied and very clinically meaningful option for patients and clinicians treating this distinct molecular subtype of colorectal cancer." Calgary-based medical oncologist, Dr. Hatim Karachiwala added,"For patients with unresectable or advanced hepatocellular carcinoma improving outcomes continues to be a critical priority. Data from CheckMate-9DW provides useful insights into how the OPDIVO ® plus YERVOY ® dual immunotherapy strategy might be considered as part of the initial treatment approach." BMS introduced immunotherapy in Canada in 2012 with the approval of YERVOY ®, ushering in a new era of cancer treatment providing an important option for patients with advanced cancers. The 2016 approval of the first dual immunotherapy regimen—YERVOY ® plus OPDIVO ® —further expanded this foundation. These latest indications further expand the reach of the combination to include MSI-H/dMMR colorectal and liver cancer patients. Immunotherapy Advances Welcomed by Patient Groups "In a country where colorectal cancer remains one of the most commonly diagnosed cancers and a leading cause of cancer death for both men and women 2, this news represents a much-needed advancement," said Barry Dr. Stein, President and CEO, Colorectal Cancer Canada. "This dual immunotherapy approach provides eligible patients and their care teams with a new, clinically validated strategy to take action early in the treatment journey." Filomena Servidio-Italiano, President and CEO, Colorectal Cancer Resource & Action Network (CCRAN), added, "These approvals mark important progress for both the colorectal and liver cancer communities. For those facing aggressive disease, time matters. Expanding access to first-line immunotherapy—particularly with combination strategies that enhance the immune system engagement—responds to an important unmet need." "Making up approximately 75% all primary liver cancer cases 3, hepatocellular carcinoma has a significant impact on patients across the country," said Jennifer Nebesky, President and CEO, Liver Canada. "In 2024, liver cancer was projected to be diagnosed in 4,700 Canadians, with 3,700 deaths 4 —figures that speak to the need for continued progress in improving care. The approval of OPDIVO ® plus YERVOY ® as a first-line treatment provides renewed hope and a new path forward for patients and clinicians alike." In the CheckMake-8HW trial, OPDIVO ® plus YERVOY ® reduced the risk of disease progression or death by 79% compared to chemotherapy in the first-line treatment of MSI-H/dMMR metastatic colorectal cancer. In advanced hepatocellular carcinoma, the CheckMate-9DW trial showed the combination delivered a statistically significant overall survival benefit compared to tyrosine kinase inhibitors. These results highlight the potential of dual immunotherapy to drive meaningful change in early treatment across both cancers. "These approvals underscore our continued focus on advancing immunotherapy where it can make a meaningful difference," said Elaine Phillips, General Manager, Bristol Myers Squibb Canada. "By introducing OPDIVO ® plus YERVOY ® as a first-line treatment option for these two distinct and challenging gastrointestinal cancers, we are expanding access to a dual immunotherapy approach in areas with significant unmet need. This milestone reflects our commitment to delivering innovative science with real-world impact." Clinical Trials Overview OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), was evaluated in two pivotal Phase 3 trials—CheckMate-8HW and CheckMate-9DW—supporting its first-line use in MSI-H/dMMR colorectal and liver cancers. CheckMate-8HW is a global, randomized, open-label Phase 3 trial that enrolled 839 patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). The trial included an evaluation of OPDIVO ® plus YERVOY ® (n=202) versus standard-of-care chemotherapy (with or without bevacizumab or cetuximab) (n=101). The OPDIVO ® plus YERVOY ® versus investigator's choice chemotherapy with/without bevacizumab or cetuximab arm of the trial showed that the combination regimen reduced the risk of cancer progression or death by 79% compared to chemotherapy in centrally confirmed MSI-H/dMMR mCRC first-line patients (HR 0.21; 95% CI: 0.14-0.32; P<0.0001). After a median follow-up of 31.5 months, median progression-free survival (PFS) was not reached with OPDIVO ® plus YERVOY ® (95% CI: 38.4-NE) compared to 5.9 months with chemotherapy (95% CI: 4.4-7.8). Kaplan-Meier curves showed early and sustained separation starting at three months, with PFS rates of 79% vs. 21% at 12 months and 72% vs. 14% at 24 months, respectively. CheckMate-9DW is a global, randomized, open-label Phase 3 trial that enrolled 668 patients with unresectable or advanced hepatocellular carcinoma (HCC) who had not received prior systemic therapy. Patients were randomized to receive OPDIVO ® plus YERVOY ® (n=335) or investigator's choice of lenvatinib or sorafenib monotherapy (n = 333). The dual immunotherapy regimen consisted of OPDIVO ® 1 mg/kg plus YERVOY ® 3 mg/kg every three weeks for up to four doses, followed by OPDIVO ® monotherapy 480 mg every four weeks. The trial demonstrated a statistically significant improvement in overall survival (OS): median OS was 23.7 months with OPDIVO ® plus YERVOY ® versus 20.6 months with lenvatinib/sorafenib (HR 0.79; 95% CI: 0.65–0.96; p = 0.0180). The overall response rate (ORR) was 36.1% vs. 13.2% (p < 0.0001), with complete responses in 6.9% of patients receiving dual immunotherapy. Median duration of response was 30.4 months vs.12.9 months. In both trials, the safety profile of OPDIVO ® plus YERVOY ® was consistent with the known class effects of PD-1 and CTLA-4 inhibitors. Immune-mediated adverse events were generally manageable with established treatment algorithms. For more information, including prescribing and safety information related to the new indications, please consult the Canadian product monograph for OPDIVO ® here. About Bristol Myers Squibb Canada Co. Bristol Myers Squibb Canada Co. is an indirect wholly-owned subsidiary of Bristol Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol Myers Squibb Canada Co. employs close to 300 people across the country. For more information, please visit ____________ SOURCE Bristol-Myers Squibb Canada
Toronto Star
an hour ago
- Toronto Star
OTC Markets Group Welcomes Southern Cross Gold Consolidated Ltd. to OTCQX
NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Southern Cross Gold Consolidated Ltd. (TSX: SXGC; ASX: SX2; OTCQX: SXGCF), a company engaged in the acquisition and exploration of mineral properties in Australia, has qualified to trade on the OTCQX® Best Market. Southern Cross Gold Consolidated Ltd. upgraded to OTCQX from the Pink® market. Southern Cross Gold Consolidated Ltd. begins trading today on OTCQX under the symbol 'SXGCF.' U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on
Cision Canada
2 hours ago
- Cision Canada
The Home Depot Announces Second Quarter Fiscal 2025 Results; Reaffirms Fiscal 2025 Guidance Français
ATLANTA, Aug. 19, 2025 /CNW/ -- The Home Depot ®, the world's largest home improvement retailer, today reported sales of $45.3 billion for the second quarter of fiscal 2025, an increase of $2.1 billion, or 4.9% from the second quarter of fiscal 2024. Comparable sales for the second quarter of fiscal 2025 increased 1.0%, and comparable sales in the U.S. increased 1.4%. For the second quarter of fiscal 2025, foreign exchange rates negatively impacted total company comparable sales by approximately 40 basis points. Net earnings for the second quarter of fiscal 2025 were $4.6 billion, or $4.58 per diluted share, compared with net earnings of $4.6 billion, or $4.60 per diluted share, in the same period of fiscal 2024. Adjusted (1) diluted earnings per share for the second quarter of fiscal 2025 were $4.68, compared with adjusted diluted earnings per share of $4.67 in the same period of fiscal 2024. "Our second quarter results were in line with our expectations. The momentum that began in the back half of last year continued throughout the first half as customers engaged more broadly in smaller home improvement projects," said Ted Decker, chair, president and CEO. "Our teams are executing at a high level and we continue to grow market share. I would like to thank our associates for their continued hard work and dedication." Fiscal 2025 Guidance The company reaffirms its guidance for fiscal 2025, a 52-week year compared to fiscal 2024, a 53-week year. Total sales growth of approximately 2.8% Comparable sales growth of approximately 1.0% for the comparable 52-week period Approximately 13 new stores Gross margin of approximately 33.4% Operating margin of approximately 13.0% Adjusted (1) operating margin of approximately 13.4% Tax rate of approximately 24.5% Net interest expense of approximately $2.2 billion Diluted earnings-per-share to decline approximately 3% from $14.91 in fiscal 2024 Adjusted (1) diluted earnings-per-share to decline approximately 2% from $15.24 in fiscal 2024 Capital expenditures of approximately 2.5% of total sales (1) The Company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP). As used in this earnings release, adjusted operating income, adjusted operating margin, and adjusted diluted earnings per share are non-GAAP financial measures. Refer to the end of this release for an explanation of these non-GAAP financial measures and reconciliations to the most directly comparable GAAP measures. The Home Depot will conduct a conference call today at 9 a.m. ET to discuss information included in this news release and related matters. The conference call will be available in its entirety through a webcast and replay at At the end of the second quarter, the company operated a total of 2,353 retail stores and over 800 branches across all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico. The Company employs over 470,000 associates. The Home Depot's stock is traded on the New York Stock Exchange (NYSE: HD) and is included in the Dow Jones industrial average and Standard & Poor's 500 index. Cautionary Note Regarding Forward-Looking Statements Certain statements contained herein constitute "forward-looking statements" under the federal securities laws, including as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events, and use words such as "may," "will," "could," "should," "would," "anticipate," "intend," "estimate," "project," "plan," "believe," "expect," "target," "prospects," "potential," "commit" and "forecast," or words of similar import or meaning or refer to future time periods. Forward-looking statements may relate to, among other things, the demand for our products and services, including as a result of macroeconomic conditions and changing customer preferences and expectations; net sales growth; comparable sales; the effects of competition; our brand and reputation; implementation of interconnected retail, store, supply chain, technology innovation and other strategic initiatives, including with respect to real estate; inventory and in-stock positions; the state of the economy; the state of the housing and home improvement markets; the state of the credit markets, including mortgages, home equity loans, and consumer and trade credit; the impact of tariffs, trade policy changes or restrictions, or international trade disputes and efforts and ability to continue to diversify our supply chain; issues related to the payment methods we accept; demand for credit offerings including trade credit; management of relationships with our associates, jobseekers, suppliers and service providers; cost and availability of labor; costs of fuel and other energy sources; events that could disrupt our business, supply chain, technology infrastructure, or demand for our products and services, such as tariffs, trade policy changes or restrictions or international trade disputes, natural disasters, climate change, public health issues, cybersecurity events, labor disputes, geopolitical conflicts, military conflicts, or acts of war; our ability to maintain a safe and secure store environment; our ability to address expectations regarding sustainability and human capital management matters and meet related goals; continuation or suspension of share repurchases; net earnings performance; earnings per share; future dividends; capital allocation and expenditures; liquidity; return on invested capital; expense leverage; changes in interest rates; changes in foreign currency exchange rates; commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation, including compliance with related settlements; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges; the effect of adopting certain accounting standards; the impact of legal and regulatory changes, including executive orders and other administrative or legislative actions, such as changes to tax laws and regulations; store openings and closures; guidance for fiscal 2025 and beyond; financial outlook; the status of the pending acquisition of GMS Inc.; and the impact of acquired companies, including SRS, on our organization and the ability to recognize the anticipated benefits of any completed or pending acquisitions. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described in Part I, Item 1A. "Risk Factors," and elsewhere in our Annual Report on Form 10-K for our fiscal year ended February 2, 2025 and also as described from time to time in reports subsequently filed with the Securities and Exchange Commission. There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements. Non-GAAP Financial Measures These statements are also supplemented with certain non-GAAP financial measures. When used in conjunction with our GAAP financial measures, we believe these supplemental non-GAAP financial measures will help management and investors to better understand and analyze our performance. However, this supplemental information should not be considered in isolation or as a substitute for the related GAAP measures. Refer to the end of this release for an explanation and definitions of these non-GAAP financial measures and reconciliations to the most directly comparable GAAP measures. Three Months Ended Six Months Ended in millions, except per share data August 3, 2025 July 28, 2024 % Change August 3, 2025 July 28, 2024 % Change Net sales $ 45,277 $ 43,175 4.9 % $ 85,133 $ 79,593 7.0 % Cost of sales 30,152 28,759 4.8 56,549 52,744 7.2 Gross profit 15,125 14,416 4.9 28,584 26,849 6.5 Operating expenses: Selling, general and administrative 7,764 7,144 8.7 15,294 13,811 10.7 Depreciation and amortization 806 738 9.2 1,602 1,425 12.4 Total operating expenses 8,570 7,882 8.7 16,896 15,236 10.9 Operating income 6,555 6,534 0.3 11,688 11,613 0.6 Interest and other (income) expense: Interest income and other, net (25) (84) (70.2) (49) (141) (65.2) Interest expense 575 573 0.3 1,190 1,058 12.5 Interest and other, net 550 489 12.5 1,141 917 24.4 Earnings before provision for income taxes 6,005 6,045 (0.7) 10,547 10,696 (1.4) Provision for income taxes 1,454 1,484 (2.0) 2,563 2,535 1.1 Net earnings $ 4,551 $ 4,561 (0.2) % $ 7,984 $ 8,161 (2.2) % Basic weighted average common shares 992 990 0.2 % 992 989 0.3 % Basic earnings per share $ 4.59 $ 4.61 (0.4) $ 8.05 $ 8.25 (2.4) Diluted weighted average common shares 994 992 0.2 % 994 992 0.2 % Diluted earnings per share $ 4.58 $ 4.60 (0.4) $ 8.03 $ 8.23 (2.4) Three Months Ended Six Months Ended Selected sales data: August 3, 2025 July 28, 2024 % Change August 3, 2025 July 28, 2024 % Change Comparable sales (% change) 1.0 % (3.3) % N/A 0.4 % (3.1) % N/A Comparable customer transactions (% change) (1) (0.4) % (2.2) % N/A (0.5) % (1.9) % N/A Comparable average ticket (% change) (1) 1.4 % (1.3) % N/A 0.7 % (1.3) % N/A Customer transactions (in millions) (1) 446.8 451.0 (0.9) % 841.6 837.8 0.5 % Average ticket (1) $ 90.01 $ 88.90 1.2 $ 90.34 $ 89.72 0.7 ————— (1) Customer transactions and average ticket measures do not include results from HD Supply or SRS. THE HOME DEPOT, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) in millions August 3, 2025 July 28, 2024 February 2, 2025 Assets Current assets: Cash and cash equivalents $ 2,804 $ 1,613 $ 1,659 Receivables, net 5,878 5,503 4,903 Merchandise inventories 24,843 23,060 23,451 Other current assets 1,866 2,097 1,670 Total current assets 35,391 32,273 31,683 Net property and equipment 26,896 26,640 26,702 Operating lease right-of-use assets 8,662 8,613 8,592 Goodwill 19,619 19,414 19,475 Intangible assets, net 8,770 9,214 8,983 Other assets 711 692 684 Total assets $ 100,049 $ 96,846 $ 96,119 Liabilities and Stockholders' Equity Current liabilities: Short-term debt $ — $ 2,527 $ 316 Accounts payable 13,086 13,206 11,938 Accrued salaries and related expenses 2,385 2,105 2,315 Current installments of long-term debt 6,400 1,339 4,582 Current operating lease liabilities 1,336 1,242 1,274 Other current liabilities 7,639 7,704 8,236 Total current liabilities 30,846 28,123 28,661 Long-term debt, excluding current installments 45,917 51,869 48,485 Long-term operating lease liabilities 7,668 7,635 7,633 Other long-term liabilities 4,953 4,799 4,700 Total liabilities 89,384 92,426 89,479 Total stockholders' equity 10,665 4,420 6,640 Total liabilities and stockholders' equity $ 100,049 $ 96,846 $ 96,119 NON-GAAP FINANCIAL MEASURES Adjusted operating income, adjusted operating margin (calculated as adjusted operating income divided by total net sales), and adjusted diluted earnings per share are presented as supplemental financial measures in the evaluation of our business that are not required by or presented in accordance with GAAP. The Company excludes the impact of amortization expense from acquired intangible assets from adjusted operating income and adjusted operating margin, and the impact of amortization expense from acquired intangible assets, including the related tax effects, from adjusted diluted earnings per share. We do not adjust for the revenue that is generated in part from the use of our acquired intangible assets. Amortization expense, unlike the related revenue, is not affected by operations in any particular period unless an intangible asset becomes impaired, or the useful life of an intangible asset is revised. When used in conjunction with our GAAP results, we believe these non-GAAP measures provide investors with meaningful supplemental measures of our performance period to period, make it easier for investors to compare our underlying business performance to peers, and align to how management analyzes trends and evaluates performance internally. The Company provides non-GAAP financial information on this basis to facilitate comparability when we report earnings results. These non-GAAP measures should not be a substitute for their comparable GAAP financial measures. Investors should rely primarily on our GAAP results and use non-GAAP financial measures only supplementally in making investment decisions. Our calculation of non-GAAP measures may not be comparable to similarly titled measures reported by other companies and other companies may not define these non-GAAP financial measures in the same way, which may limit their usefulness as comparative measures. ————— (1) Operating margin is calculated as operating income divided by total net sales. (2) Amounts include acquired intangible asset amortization of $87 million and $174 million during the three and six months ended August 3, 2025, respectively, and $39 million during the three and six months ended July 28, 2024 related to SRS which was acquired on June 18, 2024. (3) Adjusted operating margin is calculated as adjusted operating income divided by total net sales. Our adjusted operating margin guidance for fiscal 2025 excludes an expected approximately 40 basis point impact from acquired intangible asset amortization. ————— (1) Calculated as the per share impact of acquired intangible asset amortization multiplied by the Company's effective tax rate for the period. Our adjusted diluted earnings per share guidance for fiscal 2025 excludes an expected after-tax impact of approximately $0.40 from acquired intangible asset amortization. SOURCE The Home Depot
